NASDAQ | VICL: 1.24  +0.00

Other Products

Apex®-IHN is a plasmid DNA-based infectious disease vaccine for use in the prevention of infectious hematopoietic necrosis virus disease in farm-raised salmon. Apex®-IHN was the first commercial DNA vaccine to achieve approval for sale and use in Canada, where it is currently marketed by Novartis Aqua Health. Apex®-IHN received licensure from the Canadian Food Inspection Agency in 2005.

Tetravalent dengue vaccine (TVDV) is a plasmid DNA-based infectious disease vaccine in clinical development in humans for the prevention of all 4 dengue virus serotypes. Vical manufactured TVDV under contract with the Naval Medical Research Center, who has conducted Phase 1 testing of this vaccine. TVDV utilizes Vical’s proprietary adjuvant formulation, Vaxfectin®, to increase immune responses.

ONCEPT® is a plasmid DNA-based cancer vaccine that was designed to extend the survival of dogs with oral melanoma. ONCEPT® was the first approved therapeutic cancer vaccine in either animals or humans.Our licensee Merial received approval by the U.S. Department of Agriculture for ONCEPT® in 2007.

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.